SynthesisThrombosis research2018
Testosterone therapy and venous thromboembolism: A systematic review and meta-analysis.
Synthesis in Thrombosis research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Article
- Article
- Gender-affirming hormone therapy in the transgender patient: influence on thrombotic risk.Hematology. American Society of Hematology. Education Program · 2024Review
- Testosterone Therapy Does Not Affect Coagulation in Male Hypogonadism: A Longitudinal Study Based on Thrombin Generation.The Journal of clinical endocrinology and metabolism · 2024Observational
- Article
- Article
- A thrombophilic allele of clotting Factor VII/VIIa promoting recurrent pulmonary emboli, clinical details, and a structural model of the altered protein: a case report.Journal of medical case reports · 2023Article
- Testosterone therapy increases the anticoagulant potential in men with opioid-induced hypogonadism: a randomized, placebo-controlled study.Endocrine connections · 2023Article
- Inferior mesenteric vein thrombosis in the setting of testosterone therapy.BMJ case reports · 2022Article
- Relationships between endogenous and exogenous testosterone and cardiovascular disease in men.Reviews in endocrine & metabolic disorders · 2022Review
- Sex-specific aspects of venous thromboembolism: What is new and what is next?Research and practice in thrombosis and haemostasis · 2022Review
- Glucocorticoids and Risk of Venous Thromboembolism in Asthma Patients Aged 20-59 Years in the United Kingdom's CPRD 1995-2015.Clinical epidemiology · 2022Article
- The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis.PloS one · 2022Article
- Severe Cardiac and Metabolic Pathology Induced by Steroid Abuse in a Young Individual.Diagnostics (Basel, Switzerland) · 2021Article
- Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer.The world journal of men's health · 2021Review
- Cardiovascular risk and testosterone - from subclinical atherosclerosis to lipoprotein function to heart failure.Reviews in endocrine & metabolic disorders · 2021Review
- Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry.The Journal of clinical endocrinology and metabolism · 2021Observational
- Successful thrombolysis of normotensive pulmonary embolism with life-threatening hypoxia in a young man with Klinefelter syndrome.BMJ case reports · 2021Article
- Effects of Exogenous Androgens on Platelet Activity and Their Thrombogenic Potential in Supraphysiological Administration: A Literature Review.Journal of clinical medicine · 2021Review
- Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population.Frontiers in endocrinology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTestosterone prescribing for men has dramatically increased, and there have been concerns about inappropriate use and adverse events. While regulatory bodies have warned about increased risk of venous thromboembolism (VTE), published clinical data supporting an increased risk for VTE are limited.
objectiveTo conduct a systematic review of studies examining the association between testosterone therapy in men and VTE.
methodsComprehensive searches of multiple databases were performed from inception through October 3rd, 2018. Randomized control trials (RCTs) and observational studies examining the association between exogenous testosterone (any route) and VTE. Study selection and data extraction were performed by two independent investigators. Random-effect model meta-analyses were used to estimate pooled odds ratios (OR) and 95% confidence intervals (CIs). Heterogeneity among studies was evaluated using the I
resultsSix RCTs (n = 2236) and 5 observational studies (n = 1,249,640) were included. Five RCTs were performed in men with documented hypogonadism. The observational studies included: 2 case-control studies, 2 retrospective cohorts, and 1 retrospective cohort with a nested case-control study. There was no evidence of a statistically significant association between VTE and testosterone (OR 1.41, 95%CI 0.96-2.07). Heterogeneity was high (I-squared = 84.4%). The association remained nonsignificant when the analysis was stratified by study design: RCTs (2.05, 95% CI 0.78-5.39); cohort (1.06, 95% CI 0.85-1.33); and case-control (1.34, 95% CI 0.78-2.28). The overall risk of bias was moderate.
conclusionsThe current evidence is of low certainty but does not support an association between testosterone use and VTE in men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.